Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy.

Jensen, Jeffrey D; Lynch, Michael

Jensen, Jeffrey D; Lynch, Michael.

Jensen JD; School of Life Sciences, Arizona State University, Tempe, AZ, USA. Jeffrey.D.Jensen@asu.edu.
Lynch M; School of Life Sciences, Arizona State University, Tempe, AZ, USA.

Heredity (Edinb) ; 124(5): 619-620, 2020 05.

Article in English | MEDLINE | ID: covidwho-38563

Subject(s)

Antiviral Agents/therapeutic use; Betacoronavirus/genetics; Coronavirus Infections/drug therapy; Mutation Accumulation; Mutation; Pneumonia, Viral/drug therapy; Amides/pharmacology; Amides/therapeutic use; Antiviral Agents/pharmacology; Betacoronavirus/drug effects; COVID-19; Coronavirus Infections/virology; Humans; Models, Genetic; Pandemics; Pneumonia, Viral/virology; Pyrazines/pharmacology; Pyrazines/therapeutic use; SARS-CoV-2; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Coronavirus Infections / Mutation Accumulation / Betacoronavirus / Mutation Limits: Humans Language: English Journal: Heredity (Edinb) Year: 2020 Document Type: Article Affiliation country: S41437-020-0314-z

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google